United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Report 2017

November 2017 | 113 pages | ID: UEA8717213BWEN
QYResearch

Abstracts

In this report, the United States B-Cell Maturation Antigen(BCMA) Targeted Therapies market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of B-Cell Maturation Antigen(BCMA) Targeted Therapies in these regions, from 2012 to 2022 (forecast).

United States B-Cell Maturation Antigen(BCMA) Targeted Therapies market competition by top manufacturers/players, with B-Cell Maturation Antigen(BCMA) Targeted Therapies sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Transposagen Biopharmaceuticals
• Sutro Biopharma
• Malin Corporation
• Eureka Therapeutics
• firstVentury Equity
• Five Prime Therapeutics
• Credit Suisse Securities
• Dana-Farber Cancer Institute
• Deerfield Partners
• Onyx Pharmaceuticals
• Juno Therapeutics

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Bispecific Antibodies
• Antibody Drug Conjugates
• Chimeric Antigen Receptor T-Cells

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Liver Cancer
• Respiratory Cancer
• Brain Cancer
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Report 2017

1 B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES OVERVIEW

1.1 Product Overview and Scope of B-Cell Maturation Antigen(BCMA) Targeted Therapies
1.2 Classification of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Product Category
  1.2.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Bispecific Antibodies
  1.2.4 Antibody Drug Conjugates
  1.2.5 Chimeric Antigen Receptor T-Cells
1.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Application/End Users
  1.3.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Liver Cancer
  1.3.3 Respiratory Cancer
  1.3.4 Brain Cancer
  1.3.5 Others
1.4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Region
  1.4.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
  1.4.3 Southwest B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
  1.4.5 New England B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
  1.4.6 The South B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
  1.4.7 The Midwest B-Cell Maturation Antigen(BCMA) Targeted Therapies Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of B-Cell Maturation Antigen(BCMA) Targeted Therapies (2012-2022)
  1.5.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2022)
  1.5.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate (2012-2022)

2 UNITED STATES B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Average Price by Players/Suppliers (2012-2017)
2.4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Competitive Situation and Trends
  2.4.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Rate
  2.4.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers B-Cell Maturation Antigen(BCMA) Targeted Therapies Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Region (2012-2017)
3.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Market Share by Region (2012-2017)
3.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price by Region (2012-2017)

4 UNITED STATES B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Market Share by Type (2012-2017)
4.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price by Type (2012-2017)
4.4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Type (2012-2017)

5 UNITED STATES B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Application (2012-2017)
5.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Transposagen Biopharmaceuticals
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Sutro Biopharma
  6.2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Malin Corporation
  6.3.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Eureka Therapeutics
  6.4.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 firstVentury Equity
  6.5.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Five Prime Therapeutics
  6.6.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Credit Suisse Securities
  6.7.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Dana-Farber Cancer Institute
  6.8.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Deerfield Partners
  6.9.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Onyx Pharmaceuticals
  6.10.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Juno Therapeutics

7 B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES MANUFACTURING COST ANALYSIS

7.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume, Revenue Forecast (2017-2022)
11.2 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Forecast by Type (2017-2022)
11.3 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Forecast by Application (2017-2022)
11.4 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (K Units) by Type (2012-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Market Share by Type (Product Category) in 2016
Figure Bispecific Antibodies Product Picture
Figure Antibody Drug Conjugates Product Picture
Figure Chimeric Antigen Receptor T-Cells Product Picture
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Application in 2016
Figure Liver Cancer Examples
Table Key Downstream Customer in Liver Cancer
Figure Respiratory Cancer Examples
Table Key Downstream Customer in Respiratory Cancer
Figure Brain Cancer Examples
Table Key Downstream Customer in Brain Cancer
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Million USD) by Region (2012-2022)
Figure The West B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players/Suppliers
Figure 2017 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players/Suppliers
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players/Suppliers
Figure 2017 United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players/Suppliers
Table United States Market B-Cell Maturation Antigen(BCMA) Targeted Therapies Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market B-Cell Maturation Antigen(BCMA) Targeted Therapies Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share of Top 3 Players/Suppliers
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers B-Cell Maturation Antigen(BCMA) Targeted Therapies Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Category
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Region (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Region (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Region (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Region in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Region (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Region (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Region in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price (USD/Unit) by Region (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Type (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Type (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Type (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Type in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Type (2012-2017)
Figure Revenue Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Type (2012-2017)
Figure Revenue Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Type in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price (USD/Unit) by Types (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Type (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Application (2012-2017)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application in 2016
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Application (2012-2017)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate by Application (2012-2017)
Table Transposagen Biopharmaceuticals Basic Information List
Table Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Sutro Biopharma Basic Information List
Table Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Malin Corporation Basic Information List
Table Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Eureka Therapeutics Basic Information List
Table Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table firstVentury Equity Basic Information List
Table firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Five Prime Therapeutics Basic Information List
Table Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Credit Suisse Securities Basic Information List
Table Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Dana-Farber Cancer Institute Basic Information List
Table Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Deerfield Partners Basic Information List
Table Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Onyx Pharmaceuticals Basic Information List
Table Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Growth Rate (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in United States (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in United States (2012-2017)
Table Juno Therapeutics Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure Manufacturing Process Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure B-Cell Maturation Antigen(BCMA) Targeted Therapies Industrial Chain Analysis
Table Raw Materials Sources of B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Players/Suppliers in 2016
Table Major Buyers of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Table Distributors/Traders List
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Price (USD/Unit) Trend Forecast (2017-2022)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Type in 2022
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Application in 2022
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Share Forecast by Region (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Share Forecast by Region (2017-2022)
Figure United States B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources